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Abstract Despite recent developments and new treatments
in ophthalmology there is nothing available to cure retinal
degenerations like Retinitis Pigmentosa (RP) yet. One of the
most advanced approaches to treat people that have gone
blind due to RP is to replace the function of the degen-
erated photoreceptors by a microelectronic neuroprosthetic
device. Basically, this subretinal active implant transforms
the incoming light into electric pulses to stimulate the
remaining cells of the retina. The functional time of such
devices is a crucial aspect. In this paper the laboratory
and clinical reliability of the two active subretinal implants
Alpha IMS and Alpha AMS is presented. Based on clin-
ical data the median operating life of the Alpha AMS is
estimated to be 3.3 years with a one-sided lower 75 % con-
fidence level of 2.0 years. This data shows a significant
improvement of the device lifetime compared to the previ-
ous device Alpha IMS which shows a median lifetime of 0.6
years with a lower confidence bound (75 %) of 0.5 years.
The results are in good agreement with laboratory data from
accelerated aging tests of the implant components, showing
an estimated median lifetime for Alpha IMS components of
0.7 years compared to the improved lifetime of Alpha AMS
of 4.7 years.
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1 Introduction
In the hereditary disease Retinitis Pigmentosa (RP) the pho-
toreceptors progressively degenerate, resulting in blindness
in adult life, although the rest of the inner retina (bipolar
and ganglion cells) and visual pathway downstream of the
retina usually stay mostly intact. Although several promis-
ing approaches are studied, e.g. gene therapy (Stieger and
Lorenz 2010; Hufnagel et al. 2012; Sundaram et al. 2012),
electrostimulation (Schatz et al. 2011) or stem cell thera-
pies (Ramsden et al. 2013) there is no therapy available to
treat or cure the disease itself yet. One of the most advanced
approaches to help blind RP patients is to replace the degen-
erated photoreceptors by an electronic chip that stimulates
the remaining retina cells by charges – a technology that
resulted in CE-marked (Stingl et al. 2013; Zrenner et al.
2011; Humayun et al. 2012; www.pixium-vision.com) and
FDA approved products (Ho et al. 2015). Different designs
of such retinal implants can be distinguished by the position
of the charge-transferring electrodes in: a) subretinal (Stingl
et al. 2013; Zrenner et al. 2011), b) epiretinal (Humayun
et al. 2012; www.pixium-vision.com; Ho et al. 2015) and
c) supra-choroidal (Ayton et al. 2014; Ohta et al. 2007).
A review about the several research groups and their dif-
ferent approaches is given in Chuang et al. (2014). Retina
Implant AG (Reutlingen, Germany) has early on focused on
a subretinal chip. Our designs include 1500 to 1600 on-chip
photodiodes, each in combination with an amplifying tran-
sistor and a charge-transferring electrode. This combination
allows an outstanding number of densely packed electrodes
and hence the possibility to achieve a high spacial resolution
(Stingl et al. 2013).
For all active implants that are in direct contact with
body fluids degradation of materials is a critical issue
and the electronics need sufficient protection. To achieve
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a high reliability and durability of active implants, it is
generally approved to put the complete implant in a her-
metically sealed housing out of metal or ceramics to protect
the included electronics, with only the passive components
being outside the housing (Ho et al. 2015; Green et al.
2013). For retinal implants this type of construction could
be adopted, but would require one cable connection for each
stimulating electrode. Therefore a retinal implant consist-
ing of a system with a hermetic housing and a reasonable
number of passive stimulation electrodes would require
an excessive amount of feedthroughs – an amount, which
cannot be integrated inside the eye realistically.
Our two generations of subretinal implants have 1500
and 1600 stimulation electrodes respectively and a corre-
sponding number of photodiodes on chip. As light has to fall
on the photodiodes and the chip with its stimulation elec-
trodes needs to be in direct contact with the retinal tissue,
a hermetic housing is not an option. Instead only conformal
coatings of the chip can be used to protect it from corrosion.
Typical coatings that are used in this environment are a com-
bination of several organic and inorganic materials that are
biocompatible as well as robust in harsh environments. Such
a non-standard system is a novelty for neural prostheses and
the effects of active electronic parts in a wet environment are
still under investigation. Especially the type of failure mech-
anisms that occur in such a system has to be investigated.
Typical failure mechanisms of active electronics that are in
direct contact to saline solution are corrosion and migration
of the conductive materials and delamination between lay-
ers due to water diffusion. In contrary to a hermetic housing,
the process of corrosion of active electronics is a continu-
ous process that is not exactly predictable. Such a statistical
process can be described in reliability engineering by prob-
ability distributions that depend on the type of failure mode.
From this distribution a characteristic lifetime called the
mean time to failure (MTTF) can be determined. To give
a more vivid value, instead of the MTTF we describe all
product lifetimes in this paper in terms of the median value,
being the time when 50 % of the devices failed.
The visual results of the clinical study are already pub-
lished in Stingl et al. (2015). In this paper we present the
first data about the functional lifetime of the subretinal
Alpha IMS and Alpha AMS implant. We estimated the sys-
tem lifetime from laboratory component tests and compared
it with the lifetimes of the implant systems in clinical trials.
2 Materials and methods
In this publication two product generations are considered,
both manufactured by Retina Implant AG (Reutlingen, Ger-
many) which are taken as two datasets for evaluation of
the clinical and laboratory reliability. The first one is Alpha
IMS. Technical development, which consists mainly on
modifications of the design and optimizing the control sig-
nals of the CMOS chip, led to the second generation, Alpha
AMS. A schematic picture of the implant system is shown
in Fig. 1. Both systems consist of a CMOS chip which is
fixed on top of a foil substrate. In the two implant systems
the CMOS chip has 1500 and 1600 photodiodes on an area
of 3x3mm2, respectively. The chip is placed subretinally in
the eye. The photodiodes are collecting the light that falls
through the natural pathway of the eye onto the chip. The
amplified charge signal is then transferred by an electrode
to the adjacent retinal layer. The retroauricularly placed sub-
dermal coil that is enclosed in a hermetic ceramic housing is
providing energy and control signals for the chip and is con-
trolled by an external handheld device. The coil is connected
by a power supply cable to the foil substrate. It consists of
medical grade silicone encasing helically coiled gold wires.
A return electrode is implanted close to the ceramic housing.
2.1 Competing risk analysis of laboratory data
The whole system is divided into several components and
all critical components are tested separately in laboratory
environment, some of them under accelerated aging con-
ditions at 60◦C to shorten test time (Carfagno and Gibson
1980; Hemmerich 1998). The tested components are: the
CMOS chip, the foil substrate and the power supply cable.
For these components lifetime is determined by laboratory
experiments. For each tested component a specific life-
time distribution is determined from the laboratory data. As
characteristic parameter for the distributions the value of
the median life was used, which means that with a prob-
ability of 50 % the products will function for that period
of time. The ceramic housing and the return electrode are
expected to have a much longer component lifetime com-
pared to the critical components. In the clinical study no
failure due to ceramic housing or the return electrode was
obeserved. Therefore they are neglected in the calculation
of the reliability.
To determine the median lifetime of the CMOS chip sev-
eral chips were tested under accelerated aging conditions
at 60◦C. They were operated in phosphate buffered saline
Fig. 1 Components of the Alpha IMS and Alpha AMS implant sys-
tem (a: CMOS chip, b: foil substrate, c: power supply cable, e: return
electrode, d: ceramic housing)
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solution (PBS) using the normal handheld devices to guar-
antee the test conditions to be as close to normal operating
conditions as possible. They are operated at gain and sen-
sitivity levels that are close to the maximum levels that are
typical for clinical use. The time-to-failure of each chip can
be determined very precisely, because of the sudden drop
of the continuously measured stimulation signal. A Weibull
distribution (Wilker 2010) is fitted to the obtained device
lifetimes and the median time is determined. According to
the Arrhenius equation for chemical reaction rates the accel-
erated aging factor (AAF) between operating condition at
TO = 37◦C and test condition at TT = 60◦C can be
approximated by the 10-degree-rule (Hemmerich 1998)
AAF = Q(TT −TO)/1010 = 2T/10 = 4.92 (1)
A reaction rate coefficient of Q10 = 2 is commonly
assumed for aging of systems under moderate aging con-
ditions and is typically applied for medical devices (Hem-
merich 1998). We assumed a maximum runtime of 8 hours
per day, which is based on information gathered from the
patients during the clinical trial, because due to the observed
failure mechanisms it is expected that the chip is only aging
when it is in operation.
The lifetime of the polyimide foil substrate was tested
by applying a constant voltage to all conducting traces of
the substrate and measuring the leakage current from the
foil substrate to a return electrode while the substrate is
immersed in PBS. When the polyimide substrate starts to
fail, a sudden increase of the leakage current by several
decades can be observed. We again assume an accelerated
aging factor of 4.92 but an operation time of 24h per day
since we presume that the foil substrate is also aging when
the implant is switched off. A Weibull distribution is used
to determine the median life.
The power supply cable was tested by bending tests using
an apparatus that simulates a periodic bending of a fixated
power supply cable. The lifetime distribution of the power
supply cable is approximated by an exponential distribution
because all failures are assumed to be randomly distributed.
The physical interpretation concerning our system is that
sudden failures occur for example due to ruptures of the
cables. As the number of eye movements largely depend on
deflection angle from normal eye position it is hard to find
a reliable value in literature for the typical number of eye
movements per year. Considering the rather slow stimula-
tion frequency of the implant, corresponding to a high eye
fixation time, and the time the retinal implant is typically
used, we estimate about 2 million eye movements per year
(Ro¨tting 2001; Takahashi and Atsumi 1997; Kokelmann and
Wrobel 2012).
The lifetime of the whole system of our subretinal
implant is estimated from these laboratory data by a com-
peting risk analysis (NIST/SEMATECH 2013). It assumes
that all components are connected in series and the whole
system fails when one of the components fails. Therefore
the reliability of the whole system SSys is the product of the
reliabilities of all components.
SSys(t) = SCMOS(t) · SFlexSubstrate(t) · SPowerCable(t) (2)
For each component the fraction of survived devices at
time t is described by the reliability S(t) which is deter-
mined by fitting of the laboratory lifetime data. Depending
on the type of distribution of the data points for each com-
ponent either Weibull or Exponential distribution is chosen
to determine the median life where S(t) = 50 %. All
component reliabilities are multiplied time-dependent. The
resulting median life τ of the complete implant system can
then be determined by
SSys(τ ) = 50 %. (3)
2.2 Calculation of the clinical reliability
The multicenter trial (www.clinicaltrials.gov, NCT0102
4803) and its interim results are described in detail by
Stingl et al. (2015). They showed, that with the retinal
implant Alpha IMS a rudimentary vision could be restored
in patients, that are blind from hereditary degenerations of
photoreceptors. Patients were able to localise and recog-
nize high-contrast objects. In this publication we focus on
the clinical reliability of the two implants. Alpha IMS was
implanted in 29 patients (in 2010-2013), but due to one
reimplantation 30 implant systems are considered in the
evaluation. Alpha AMS on the other hand was implanted
in 10 patients during the multicenter trial (since 2014) and
additionally in five patients as part of an ongoing clin-
ical trial at NIHR Oxford (National Institute for Health
Research, Oxford, GB, NCT02720640). For evaluation of
the reliability both trials are analyzed in one dataset, since
the device (Alpha AMS) is the same. One additional implan-
tation of Alpha AMS that is not part of a clinical trial was
also included for the calculation of the clinical reliability.
The functional life of the implants was defined by cal-
culating the days between implantation and reported failure
of the implant. The patients can clearly detect a malfunc-
tion of the implants by themselves when they no longer have
any visual perception. Additional measurements using elec-
troretinography equipment are carried out in the clinic to
verify the reported failure of the device (Stingl et al. 2016).
If a malfunction of the device is confirmed, the time of fail-
ure as reported by the patient is noted for the evaluation of
the clinical reliability. In that way the lifetime of all implants
in clinical use are continuously collected and evaluated.
The clinical reliability is estimated by two independent
methods. One method is an actuarial analysis, resulting in
a Kaplan-Meier-Plot. As the mean system lifetime for the
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Alpha AMS system cannot yet be predicted by the Kaplan-
Meier method, a second method is used for estimating the
expected mean lifetime using an exponential distribution.
Clinical reliability evaluated by Kaplan-Meier-Method
We evaluated the reliability of the implants by an actuarial
analysis in compliance with ISO 5841-2:2014 with slight
adaptation to our specific case. The devices were catego-
rized depending on the status of the implant at each time
step into the categories mentioned in Table 1.
In actuarial analysis the key variable to describe the
reliability is the cumulative survival rate versus time. It
can always be used when the distribution of the data-
points is not known in advance and a continuous evaluation
is possible even when not all devices have failed. The
Kaplan-Meier estimation is an empirical (non-parametric)
procedure (Kaplan and Meier 1958). The cumulative sur-
vival corresponds to the estimated probability that a device
is surviving for a specific period. It is a product of the sur-
vival fractions P(t), which describe the probability, that a
device is surviving one specific time interval, calculated by
P(t) = 1 − C(t)
U(t)
(4)
with the number of failed devices C(t) in that time inter-
val and the units at risk U(t) which describe the number of
devices that could have failed in that time step. The cumula-





P (tn) = P(t) · P(t − 1) · . . . · P(1) (5)
Due to the small number of patients the confidence inter-
vals, calculated by Greenwood’s formula (Kaplan andMeier
1958)




U(tj )(U(tj ) − C(tj )) (6)
Table 1 Device categorization for Kaplan-Meier-Method. Depending
on the device function each implanted system is categorized at each
time step
Category
A Device in service, no complication reported.
B Device removed from service for reasons not
related to the device functioning.
C Device with malfunction confirmed.
D Patient died, death unrelated to the
functioning of the device.
L Device is lost to follow-up. No complication
or malfunction recorded.
are set to 68 % which is equivalent to one standard deviation
σ(t).
Estimation of system lifetime from clinical data The
expected lifetime of the implants in the clinical trial was
estimated assuming an exponential life distribution, also
called HPP model (Homogeneous Poisson Process). It is a
common method in reliability engineering to verify that a
system meets the desired reliability requirements. Also, the
clinical reliability of the system Alpha IMS shows a clearly
exponential behavior. For that reason the same behavior is
expected for the Alpha AMS system. In this model it is
assumed, that the failure rate is constant. Due to this con-
stant failure rate it is possible to estimate the characteristic
lifetime of a system by adding all accumulated lifetimes of
all measured devices and divide it by the number of failed
devices. A one-sided lower confidence bound is calcu-
lated by dividing the accumulated lifetimes by a factor that
depends on the number of occurred failures and the desired
confidence level. It can be calculated from the Chi-Square
distribution (NIST/SEMATECH 2013).
3 Results
3.1 Laboratory results of the components of Alpha IMS
and Alpha AMS
A measured operational lifetime of the Alpha IMS CMOS
chips of in average 723.5 h at 60◦C (Median) equals 3559.6
h at 37◦C for the assumed accelerated aging factor of 4.92.
For an operation time of maximum 8 hours per day the
median lifetime of the Alpha IMS CMOS chip can thus be
estimated to 1.22 years.
The observed median lifetime of the Alpha IMS foil sub-
strate was 226 days (60◦C). Again an acceleration factor of
4.92 was used. With this we expect a median lifetime of 3.05
Table 2 Median lifetime τ at which a given percentage S(τ) of Alpha
IMS and Alpha AMS devices is still functioning. The total system life-
time is calculated by a product of the component reliabilities according
to Eq. 2
Component Alpha IMS Alpha AMS
τ [years] τ [years]
CMOS chip 1.22 (50 %) 6.04 (50 %)
Foil substrate 3.05 (50 %) 12.7 (50 %)
Power supply cable 1.57 (50 %) 7.04 (50 %)
Total median system 0.7 years 4.7 years
lifetime S = 50 %
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Fig. 2 Duration of function of all implanted Alpha IMS systems. Almost all of them are reported as failed (Category C, blue), two are not
functioning due to other reasons (Category B, yellow) and from one no malfunction was reported (Category A, green) from the patient
years. To ensure the correctness of the applied acceleration
factor additional tests at 37◦C were carried out, correspond-
ing to real time aging. At this setting an acceleration factor
of 4.8 could be determined.
For the power supply cable in average 3.14 million bend-
ing cycles could be performed until the cables failed. With
expected 2 million eye movements per year this results in a
median lifetime of 1.57 years.
The laboratory lifetime for the Alpha AMS components
were determined correspondingly. All results for Alpha IMS
and Alpha AMS components are summarized in Table 2.
The system lifetime was then calculated as described in the
methods section by a competing risk analysis. For Alpha
IMS the median system lifetime is estimated to 0.7 years
and for Alpha AMS 4.7 years.
3.2 Clinical results of the Alpha IMS and Alpha AMS
clinical trials
In Figs. 2 and 3 the duration of function of all implanted
Alpha IMS and Alpha AMS systems up to now are shown.
The colors refer to the categories described in Table 1.
Arrow heads on the lines of category “A” devices (green)
indicate, that these devices are still functioning and the mea-
surement is ongoing. Almost all of the Alpha IMS implant
systems are reported as failed, while for Alpha AMSmost of
the implants are still functioning. Three of the 16 implants
are no longer working. However only one of these fail-
ures could be attributed to a malfunction of the device the
other two devices were damaged possibly due to procedu-
ral errors. For that reason these two implants are considered
Fig. 3 Duration of function of all implanted Alpha AMS systems. Except three systems all of them are still functioning (Category A, green), two
failed due to procedural errors (Category B, yellow) and only one implant failed due to technical reasons (Category C, blue)
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Fig. 4 Failure mechanisms of explanted Alpha IMS implants. All
explanted Alpha IMS systems were analyzed and degradations on
implant components were used to determine the dominating failure
mechanisms of each implant. The most critical component of the
Alpha IMS system was corrosion of the CMOS chip
as censored data in the evaluation of the Kaplan-Meier-Plot,
because the malfunction is not related to the implant (ISO
5841-2:2014, category B, induced malfunction). However
for the estimation of the mean device functionality time
using an exponential model we included these devices as
failures to include all possible failure mechanisms.
Most of the failed implants during the clinical trial were
explanted to analyze the failure mechanisms. In Fig. 4 the
relative percentage of all observed failure mechanisms of
the explanted Alpha IMS devices are shown. It can be seen,
that the most critical component of the implant system is the
CMOS chip itself. In 57 % of the devices chip corrosion is
observed.
Fig. 5 Kaplan-Meier-Plot of Alpha IMS and Alpha AMS devices. The
cumulative survival rate describes the percentage of implant systems
that functioned until month t . The error bars are calculated according
to Greenwood’s formula. For the Alpha IMS system 50 % of the sys-
tems failed after 8 months, while for Alpha AMS only one technical
device failure occurred until now. The time when 50 % of the Alpha
AMS devices will be failed is not yet predictable
3.3 Clinical reliability of Alpha IMS and Alpha AMS
Kaplan-Meier-Method Since the Alpha IMS subretinal
implant was implanted already several years ago, the
patients are no longer monitored. But, apart from one
implant all of them are already reported as failed. With the
clinical trial for Alpha AMS still ongoing the presented
numbers are not final. Only data until June 2016 could be
evaluated. The individual data are shown in Fig. 2 for Alpha
IMS and in Fig. 3 for Alpha AMS.
The cumulative survival of the Alpha IMS and the Alpha
AMS is plotted in Fig. 5 as a Kaplan-Meier-Plot. The num-
ber of functional Alpha IMS devices decreased continuously
during the first year after implantation according to an
exponential behavior. The cumulative survival rate of 50 %
(Median) was attained after 8 months mirroring the labora-
tory data where we estimated a lifetime of the total system
of 0.7 years = 8.4 months.
For Alpha AMS only one device failure due to malfunc-
tions of the system has occurred, thereby the survival rate
of the devices is 92 % with a maximum implanted lifetime
of 28 months. The median lifetime of 50 % survival is not
predictable yet.
Lifetime estimation from clinical data As described in
the methods an exponential model is used to estimate the
system lifetime of the implants from clinical data. For Alpha
IMS the total runtime of 30 devices is 23 years with 29 fail-
ures resulting in a median lifetime of 0.6 years. The lower
confidence bound for 75 % is 0.5 years. For Alpha AMS and
Fig. 6 Median device functionality time of Alpha IMS and Alpha
AMS with lower 75 % confidence level (CL) estimated from clini-
cal data including technical and procedural related failures. For Alpha
IMS the median device functionality time is estimated to be 0.6 years
and a lower 75 % confidence bound of 0.5 years and for Alpha AMS
the median lifetime is expected to be 3.3 years with a lower 75 %
confidence bound of 2.0 years
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16 patients a total runtime of 14.5 years was accumulated.
Two of the implants failed after procedural errors and one
implant failed due to technical reasons, resulting in an esti-
mated median lifetime of 3.3 years and a lower confidence
bound for 75 % of 2.0 years. This suggests an increase in
lifetime by at least a factor of 4. These results are depicted
in Fig. 6.
4 Discussion
Up to now only three retinal devices have a market
approval. Several other approaches are under develop-
ment and no long-term reliability data are available (Ayton
et al. 2014; Guenther et al. 2012; Luo and da Cruz 2014;
Menzel-Severing et al. 2012; Yue et al. 2016). The other
commercially available retinal prostheses use an external
camera in combination with an epiretinally placed elec-
trode unit (Ho et al. 2015). In that case it is possible to
encapsulate all implanted electronics in a hermetic housing,
reducing the parts that are in direct contact with body flu-
ids to passive stimulation electrodes. Thereby a long device
lifetime can be reached (Ho et al. 2015). However, although
the visual field can be larger for the epiretinal approach,
the drawback of such a configuration is that it cannot be
easily scaled up to a large number of electrodes, subse-
quently limiting the achievable visual acuity. Our approach
of a subretinal implant already now allows a large number
of stimulation electrodes and it has been demonstrated, that
a Snellen visual acuity of 20/546 is possible (Stingl et al.
2013). Additionally it has the advantage that the natural eye
movements can be utilized. Considering the lack of alter-
native treatments for people who are blind due to retinitis
pigmentosa a device with a long lifetime is crucial.
However, the first generation of the subretinal implant,
the Alpha IMS, did not meet this criterion. In the patient
the Alpha IMS lasted less than a year (median lifetime 0.6
years with a lower 75 % confidence bound of 0.5 years).
Since the visual results of the Alpha IMS implant itself were
promising (Stingl et al. 2015), technical developments led
to the second subretinal implant Alpha AMS. The clinical
trial is not yet finished, but the clinical data of the Alpha
AMS system that are available up to now suggest a median
system lifetime of 3.3 years with a lower 75 % confidence
bound of 2.0 years. These results mean that the lifetime of
the implants could be increased at least by a factor of 4.0.
The clinical results are in good agreement with our lab-
oratory results, which are based on accelerated aging tests
and a competing risk analysis. The laboratory result of
the estimated system lifetime is slightly higher because
they include only technical failures, while in the calcula-
tion of the device lifetime from clinical data also failures
due to procedural errors are included. The laboratory results
suggest a total median lifetime of the Alpha IMS system
of 0.70 years. This shows that our laboratory experiments
can give an acceptable estimation of the actual clinical reli-
ability. Therefore we expect that we can also infer from the
laboratory experiments from Alpha AMS to the expected
clinical reliability. Also the failure mechanisms that are
observed in the clinical trial at Alpha IMS systems match
the failure mechanisms determined in laboratory tests which
shows the suitability of the laboratory model. In laboratory
experiments the CMOS chip showed the shortest lifetime
(see Table 2), and in the clinical trial the CMOS chip was
the dominating failure mechanism (Fig. 4). Also for Alpha
AMS the results of laboratory tests, which show an expected
median lifetime of 4.7 years, are in good agreement with
the clinical data that are available up to now. Hence, labo-
ratory tests and results from the ongoing clinical trial show
that a lifespan of several years is now possible with the
Alpha AMS system. Taking into account the possible option
of reimplantation, which is rather uncomplicated since the
implant is only held in place by the inner eye pressure, the
Alpha AMS is a considerable option for blind RP patients.
Further increase of the lifetime of the implant might be pos-
sible through the implementation of sophisticated coating
materials as additional passivation layers, that can better
withstand the harsh conditions. Currently several possi-
bilities are under developement, like ultrananocrystalline
diamond (Xiao et al. 2006), SiC coatings (Lei et al. 2016) or
encapsulation of the electronics in parylene C (Chang et al.
2013). In addition with further opimizations of the design
to avoid corrosion and a possible reduction of control volt-
ages another considerable increase in the lifetime might be
possible.
5 Conclusion
In this paper we showed reliability estimations for the
subretinal implants Alpha IMS and Alpha AMS (Retina
Implant AG, Reutlingen). The clinical reliability was deter-
mined by actuarial analysis and using an exponential distri-
bution to estimate the expected system lifetime. Laboratory
data of implant components were combined in a compet-
ing risk analysis. From clinical, as well as from laboratory
data we can estimate a device functionality of several years
of the Alpha AMS system which is a significant increase
compared to the previous product generation Alpha IMS.
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